# CD8+ antigen-specific T-cell clones after cyclophosphamide, with aldesleukin, in stage IV melanoma (Fred Hutchinson phase 1/2, NCI-2010-01281)

Source: https://onco.cc/trials/nct00553306/  
OnCo record `nct00553306` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A Seattle trial in 10 people with advanced melanoma testing the side effects and effect of their own laboratory-grown T cells given after cyclophosphamide, with IL-2. It ran from 2007 to 2012.

## Summary

The registry describes a phase I/II study of autologous CD8+ antigen-specific T-cell clones following cyclophosphamide conditioning, with aldesleukin, in metastatic melanoma, started in September 2007, with primary completion in August 2010, completion in March 2012 and an actual enrolment of 10 (ClinicalTrials.gov NCT00553306). Cassian Yee is listed as principal investigator and Fred Hutchinson Cancer Center as sponsor (ClinicalTrials.gov NCT00553306). No results are posted.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-11-05
- Registry id: NCT00553306
- Phase: 1/2
- Setting: Stage IV or recurrent melanoma: cyclophosphamide, then laboratory-expanded autologous CD8+ antigen-specific T cells and aldesleukin
- Sponsor: Fred Hutchinson Cancer Center
- Enrolled: 10
- Result: No results posted on ClinicalTrials.gov.

## Sources

- ClinicalTrials.gov NCT00553306: https://clinicaltrials.gov/study/NCT00553306

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)
- drugs: [Aldesleukin (high-dose IL-2)](https://onco.cc/drugs/aldesleukin/), [Cyclophosphamide](https://onco.cc/drugs/cyclophosphamide/)
- institutions: [Fred Hutchinson Cancer Center](https://onco.cc/institutions/fred-hutch/)
- terms: [Endogenous T-cell therapy](https://onco.cc/terms/endogenous-t-cell-therapy/)
- people: [Cassian Yee](https://onco.cc/people/cassian-yee/)

---
JSON: https://onco.cc/api/v1/entities/nct00553306.json